QPPV.COM KNOWLEDGE ASSESSMENT

Gabapentin: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Gabapentin: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A fall occurs in an older patient taking gabapentin, an opioid and a benzodiazepine. Which approach best supports assessment of gabapentin’s possible contribution?
Question 2 of 10 Which conclusion is most appropriate when interpreting legal proceedings concerning off-label promotion of gabapentin?
Question 3 of 10 How should the December 2019 FDA communication on serious breathing problems be interpreted in an EU regulatory assessment?
Question 4 of 10 Gabapentin was developed as a GABA analogue. Which interpretation best reflects its pharmacology?
Question 5 of 10 Why should seizure-control evidence not automatically be treated as evidence for neuropathic-pain efficacy, or vice versa?
Question 6 of 10 A company reviews multiple respiratory-depression reports involving concurrent opioid use. Which analysis would best support a sound aggregate assessment?
Question 7 of 10 A patient with focal seizures asks whether gabapentin is appropriate for any seizure type. Which response best reflects the article?
Question 8 of 10 A patient develops severe somnolence and ataxia after renal function deteriorates, with no recent dose change. What is the most appropriate initial pharmacological concern?
Question 9 of 10 A valid suspected adverse reaction report is received by a pharmacovigilance team. Which workflow best reflects the general operational approach described in the article?
Question 10 of 10 A team proposes making every recommended clinical detail in a gabapentin case assessment a mandatory gabapentin-specific reporting field. Which interpretation is most accurate?

Select an answer to continue.

QPPV.com